Blood
Articles in this Issue
Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma
Abstract Background: Mantle cell lymphoma (MCL) is a rare and aggressive B-cell malignancy, accounting for 6% of non-Hodgkin lymphomas (NHL)...
Atypical presentation of relapsed multiple myeloma with microangiopathic hemolytic anemia
Abstract Introduction: Multiple myeloma (MM) is a neoplastic plasma cell dyscrasia. Anemia in MM is typically due to anemia of chronic disea...
Optimizing essential, complex hematologic care for patients living with disabilities
Abstract Background: People living with disabilities face unique challenges accessing care. Using stem cell transplantation (BMT) as an exam...
Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
Abstract Introduction: Bispecific antibodies (BsAbs) are a powerful therapeutic modality in B-cell malignancies but are associated with dist...
Single-cell transcriptomics reveals erbb-driven clonal evolution and immune evasion in plasma cell leukemia
Abstract Introduction:Plasma cell leukemia (PCL) is a rare yet highly aggressive form of plasma cell dyscrasia, defined by high tumor burden...
Assessing clinical practice variation and provider comfort in the management of pediatric iron deficiency anemia in the acute care setting
Abstract Background: Iron deficiency anemia (IDA) is the most common cause of anemia in children with the highest preval...
Silent hemorrhage: Unraveling the insidious rectal bleeding in hermansky-pudlak syndrome
Abstract First described in 1959, Hermansky-Pudlak Syndrome (HPS) is an autosomal recessive disorder that affects vesicle biogenesis, result...
Adaptive rebalancing of ROS composition averts LSD1 inhibitor–induced oxidative stress in AML
Abstract Survival outcome for patients with acute myeloid leukemia (AML) remains poor overall. A notable exception is acute promyelocytic le...
Improved survival in chronic lymphocytic leukemia over two decades: A SEER-based population analysis (2000–2021)
Abstract Improved Survival in Chronic Lymphocytic Leukemia Over Two Decades: A SEER-Based Population Analysis (2000–2021)...
Sustained clinical benefit of glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab plus GemOx (R-GemOx) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): 3-year follow-up of STARGLO
Abstract Background Glofitamab, a CD20xCD3 bispecific antibody, when combined with GemOx (Glofit-GemOx) has demonstrated significant improve...
Central nervous system relapse in acute promyelocytic leukemia in the arsenic era: A case series and review of emerging evidence
Abstract Background: Acute Promyelocytic Leukemia (APML) is highly curable with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). H...
Calcineurin inhibitors reduce risk of MGUS progression to multiple myeloma in immunosuppressant users: A retrospective multi-institution cohort study
Abstract Introduction Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell disorder with a risk of progres...
Translational potential in research focused on hematological neoplastic diseases – results of automated large-scale analysis of pubmed and icite databases
Abstract Introduction Biomedical database evaluation can identify trends in clinical research, as well as emerging thera...
Cva with undetectable ADAMTS13 without hemolysis: An atypical presentation of thrombotic thrombocytopenic purpura (TTP)
Abstract Abstract Background: Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening autoimmune disorder...
Real-world outcomes of Y90-ibritumomab tiuxetan (Zevalin) in low-grade B-cell non-Hodgkin lymphoma: A single-institution experience
Abstract Introduction: Yttrium90 Ibritumomab Tiuxetan (Y90-IT) is a radiolabeled anti-CD20 monoclonal antibody designed to target CD20-posit...
HIT antibodies activate platelets by interacting with a negatively charged epitope on human PF4
Abstract Heparin-induced thrombocytopenia (HIT) is caused by IgG antibodies (Abs) that recognize platelet factor 4 (PF4)/heparin complexes a...
Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma
Abstract Introduction The LEO Comorbidity Index (LCI), comprising ten equally weighted comorbidity categories (respiratory, cardiovascular,...
Fertility outcomes following beacopp and ebeacopp chemotherapy in Hodgkin's lymphoma: A systematic review
Abstract Background: Hodgkin's disease has a high survival rate, especially if caught and treated in early stages. It can be effectively trea...
CCR5 blockade: A therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities.
Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy is standard care for relapsed or refractory hematologic malignancies....
BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Abstract Background: Zanu, a potent, specific next-generation BTK inhibitor with a favorable safety profile, is approved in over 70 countries...
Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China
Abstract Background Multiple myeloma (MM) is a malignant and life-threatening disorder of plasma cells, characterized by...
Maturing progenitor-like immunophenotypic cluster and megakaryocytic repopulating ability predict measurable residual disease in Acute Myeloid Leukemia
Abstract Introduction: Regenerative bone marrow ability after myeloablative agents is directly correlated with Measurable Residual Disease [...
Comprehensive profiling of the bone marrow microenvironment reveals an exhausted immune signature associated with tumor burden in Acute Myeloid Leukemia
Abstract Acute myeloid leukemia (AML) is a heterogeneous and aggressive disease characterized by the uncontrolled clonal expansion of hemato...
Engineered platelets as immune modulators: A novel strategy to prevent FVIII inhibitor formation in hemophilia A
Abstract Background: The development of inhibitory antibodies against factor VIII (FVIII) remains a major complication of replacement therap...
Novel EIF4A1 inhibitors with anti-tumor activity
Abstract Dysregulated protein synthesis is a hallmark of many cancers, driven by aberrant control of mRNA translation. In this study, we foc...